Johnson & Johnson (JNJ)

NYQ – Цена в реальном времени. Валюта: USD

224.26

+2.83 (1.28%)

При закрытии: May 12, 2026, 4:00 PM EDT

223.45

-0.95 (-0.42%)

До открытия: May 13, 2026, 4:55 AM EDT

08.05.2026

3 Unstoppable Dividend King Stocks to Buy Right Now for Less Than $550

Johnson & Johnson has increased its dividend for 64 consecutive years. Procter & Gamble recently extended its dividend growth streak to 70 straight years.

08.05.2026

Warren Buffett and Berkshire Hathaway Own 2 Dividend Kings That Will Never Be Sold

Warren Buffett stepped down as CEO of Berkshire Hathaway (BRK-B | BRK.B Price Prediction) on December 31, 2025, after six decades leading the conglomerate he transformed from a struggling textile mill into a $1 trillion empire.

07.05.2026

Darzalex, Erleada & New Drugs Keep J&J's Oncology Engine Charged in Q1

Darzalex and new launches fuel J&J's 17.8% oncology sales growth in Q1 as the company targets $50B in cancer sales by 2030.

07.05.2026

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

Michael Barclay, lead manager of the Columbia Dividend Income fund, favors dividend growers over high yields.

07.05.2026

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

Generation Fine launches after global survey finds nearly 4 in 5 patients living with major depressive disorder don't believe antidepressants will help them reach remission Campaign draws on expertise of Mental Health America and elevates the voices of leading mental health advocates, including Kyle Long, television studio analyst, retired National Football League (NFL) player NEW BRUNSWICK, N.J., May 7, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the launch of Generation Fine, a global campaign designed to challenge what it means to feel "fine" in depression care and empower patients to take the first step in moving beyond "good enough" by talking with their healthcare provider.

06.05.2026

Is Johnson & Johnson Still the Ultimate Safe Dividend Stock to Buy?

Johnson & Johnson is a Dividend King, with 64 consecutive years of increases. The company only spent 61% of its free cash flow in 2025 on dividend payouts.

06.05.2026

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.

Видео

02.05.2026

Positive

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

28.04.2026

Positive

Why These 3 Forever Stocks Belong on Your Watchlist

14.04.2026

Positive

Johnson & Johnson CFO on the company's robotic surgical system

14.04.2026

Positive

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
JNJ	Daiwa Securities	Outperform	undefined >> $203	October 20th 2025
JNJ	Wells Fargo	Overweight	undefined >> $212	October 3rd 2025
JNJ	Guggenheim	Buy	undefined >> $206	September 23rd 2025
JNJ	Erste Group	Buy	undefined >> undefined	July 23rd 2025
JNJ	Leerink Partners	Market Perform	undefined >> $153	May 13th 2025

Пресс-релизы

07.05.2026

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

05.05.2026

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

TREMFYA ® demonstrated significantly higher rates of combined fistula remission – complete external closure of draining fistulas and absence of fluid collection on MRI – compared to placebo at Week 24 First study of its kind in 20 years for this debilitating manifestation of Crohn's disease presented as late-breaking data at Digestive Disease Week 2026 CHICAGO, May 5, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results from the Phase 3 FUZION study evaluating TREMFYA® (guselkumab) in adults with active perianal fistulizing Crohn's disease (CD). At Week 24, TREMFYA demonstrated significantly higher rates of combined fistula remission, a highly stringent endpoint defined as complete external closure of draining fistulas and absence of fluid collection on MRI, compared to placebo.1 Remission in patients with this complicated manifestation remains difficult to achieve, and this is the first randomized control trial of an approved therapy in inflammatory bowel disease (IBD) that demonstrates efficacy in adults with active perianal fistulizing Crohn's disease in 20 years.

$Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease$

05.05.2026

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn's disease who have had inadequate response to two or more systemic therapy classes JNJ-4804 is the first and only fixed dose co-antibody designed to deliver molecular synergy in IBD by blocking the complementary IL-23 and TNF pathways Data from Phase 2b DUET studies show potential to address a critical unmet need and support advancement to Phase 3 trials CHICAGO, May 5, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced Phase 2b data from two studies evaluating JNJ-4804, an investigational co-antibody therapy targeting both interleukin-23 (IL-23) and tumor necrosis factor-alpha (TNF-α), in patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) that is refractory to systemic therapies.1 , 2 The late-breaking presentations from the DUET-UC and DUET-CD studies were among the 32 company-sponsored abstracts being presented at Digestive Disease Week (DDW) 2026. In both studies at Week 48, JNJ-4804 showed meaningful improvements across multiple clinical and endoscopic measures for a subpopulation of patients who are considered highly refractory and have had inadequate response to two or more systemic therapy classes.

05.05.2026

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson announces results from the first clinical study of the investigational OTTAVA™ Robotic Surgical System.

Johnson & Johnson (JNJ)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Johnson & Johnson (JNJ)

3 Unstoppable Dividend King Stocks to Buy Right Now for Less Than $550

Warren Buffett and Berkshire Hathaway Own 2 Dividend Kings That Will Never Be Sold

Darzalex, Erleada & New Drugs Keep J&J's Oncology Engine Charged in Q1

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

Is Johnson & Johnson Still the Ultimate Safe Dividend Stock to Buy?